Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $16,676.66 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 637 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $26.18, for a total transaction of $16,676.66. Following the sale, the insider now owns 75,294 shares of the company’s stock, valued at approximately $1,971,196.92. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Catriona Yale also recently made the following trade(s):

• On Friday, August 23rd, Catriona Yale sold 8,851 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.53, for a total transaction of $243,668.03.
• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.51, for a total transaction of $143,052.00.

Akero Therapeutics Price Performance

Shares of AKRO stock opened at $27.34 on Monday. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of -8.54 and a beta of -0.26. Akero Therapeutics, Inc. has a 12 month low of $11.25 and a 12 month high of $53.77. The company has a quick ratio of 24.89, a current ratio of 24.89 and a debt-to-equity ratio of 0.04. The stock has a 50-day moving average price of $25.99 and a 200 day moving average price of $23.94.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Friday, August 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.09. Research analysts expect that Akero Therapeutics, Inc. will post -3.64 EPS for the current year.

Analyst Upgrades and Downgrades

AKRO has been the topic of a number of research analyst reports. Wolfe Research began coverage on Akero Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Akero Therapeutics in a report on Thursday, June 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a report on Monday, August 12th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Akero Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $41.13.

Institutional Trading of Akero Therapeutics

A number of institutional investors have recently bought and sold shares of AKRO. Janus Henderson Group PLC lifted its stake in shares of Akero Therapeutics by 42.2% in the 1st quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company’s stock valued at $154,589,000 after purchasing an additional 1,815,569 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Akero Therapeutics by 10.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,060,479 shares of the company’s stock valued at $102,569,000 after purchasing an additional 384,555 shares during the last quarter. Vanguard Group Inc. lifted its stake in Akero Therapeutics by 19.0% in the first quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock valued at $92,702,000 after buying an additional 584,875 shares during the period. RTW Investments LP bought a new position in Akero Therapeutics during the fourth quarter worth about $83,891,000. Finally, Wellington Management Group LLP grew its position in shares of Akero Therapeutics by 247.7% during the 4th quarter. Wellington Management Group LLP now owns 2,881,989 shares of the company’s stock worth $67,294,000 after buying an additional 2,053,028 shares during the period.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.